Creation and Validation of a Prebiopsy Nomogram for Predicting High-Risk Prostate Cancer in African American Men
Abstract
Over 1 million prostate biopsies are performed annually and up to 70% of them are deemed unnecessary because many biopsies are negative or only have evidence for indolent prostate cancer (PCa). Risk calculators are one tool that can help men make decisions about whether to undergo their biopsy for an elevated prostate specific antigen (PSA) based on their reported probability of having clinically significant (csPCa), i.e. Gleason grade group 2-5 PCa. The Prostate Cancer Prevention Trial Risk Calculator version 2.0 (PCPT RC) is a popular risk calculator model. Since the grant was initially funded, 2 additional calculators have become popular including the Prostate Biopsy Collaborative Group (PBCG), which uses the same variables as the PCPT, and the Kaiser Permanente Prostate Cancer (KPPC) risk calculators. Our preliminary data on the PCPT RC performance in a multi-ethnic cohort showed that the PCPT RC seemed to have a lower accuracy in Black men. We hypothesized that since Black race or African ancestry is a term in the PCPT risk calculator model and simply adds a fixed probability adjustment across the entire risk distribution, that a risk calculator developed in a Black cohort would outperform these popular risk calculators. In Aim 1, we will assess the accuracy of a popular prostate biopsy risk calculator (Prostate Cancer Prevention Trial Risk Calculator 2.0) in Black men aged 40-79 with elevated prostate specific antigen (PSA) or abnormal digital rectal exam for the detection of Gleason grade group (GG) 2-5 prostatecancer (PCa).
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2022
- Accession Number
- AD1165157
Entities
People
- Adam B Murphy
- Peter H Gann
Organizations
- University of Chicago